Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
Teva Releases Q1 2025 Aide Memoire
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
TTeva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.